SCHEMBL1132841

SCHEMBL1132841

COc1cc2c(N3CCN(C(=S)NCc4cccnc4)CC3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.87

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 20/20 0.87
PDGFRA P16234 4/20 0.79
KIT P10721 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711340 0.93 PDGFRB (1.00) PDGFRBPDGFRA
SCHEMBL12260222 0.92 PDGFRB (0.74) PDGFRBPDGFRAKIT
SCHEMBL12260196 0.89 PDGFRB (1.00) PDGFRBPDGFRA
SCHEMBL2921329 0.89 PDGFRB (1.00) PDGFRBPDGFRAKIT
SCHEMBL12861678 0.88 PDGFRB (0.81) PDGFRBPDGFRA
SCHEMBL6709538 0.87 PDGFRB (1.00) PDGFRB
SCHEMBL2920599 0.87 PDGFRB (0.92) PDGFRBPDGFRAKIT
SCHEMBL2917932 0.87 PDGFRB (0.92) PDGFRBPDGFRAKIT
Hydrochloric Acid SCHEMBL2923894 0.85 PDGFRB (0.93) PDGFRBPDGFRAKIT
SCHEMBL6713140 0.85 PDGFRB (0.93) PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309568-B1 [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor MILLENNIUM PHARM INC (US) 2011-02-16 EP claimed
US-8022071-B2 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-20 US disclosed
US-8022071-B2 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-20 US disclosed
US-20090176780-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-07-09 US disclosed
US-20090176780-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-07-09 US disclosed
US-7329655-B2 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-12 US disclosed
US-7329655-B2 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-12 US disclosed
US-20040176594-A1 Nitrogenous heterocyclic compounds MILLENNIUM PHARMACEUTICALS, INC. 2004-09-09 US disclosed
EP-1309568-A2 NITROGENOUS HETEROCYCLIC COMPOUNDS Millennium Pharmaceuticals, Inc. (US) 2003-05-14 EP disclosed
WO-2002016361-A2 NITROGENOUS HETEROCYCLIC COMPOUNDS COR THERAPEUTICS, INC. (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176594-A1 Nitrogenous heterocyclic compounds WNK2, NPR1, NPR3 PDGFRB 9/4885PDGFRA 16/4885KIT 789/4885
US-20090176780-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS WNK2, CDK5, WNK1 PDGFRB 6/4885PDGFRA 4/4885KIT 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.